Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Allergan, Teva Unit Face FTC Claims Over Generic-Drug Delays

Jan. 24, 2017, 5:00 AM

The Federal Trade Commission continued its push against deals that delay the entry of generic drugs, while it settled claims that Endo International Plc broke antitrust laws by entering into agreements with rivals to stave off competition to two of its top-selling medications.

The FTC filed new complaints Monday against Watson Laboratories Inc., its former parent Allergan Plc, and Impax Laboratories Inc. over agreements that kept generic versions of Endo’s drugs off the market. Endo made deals with the companies to delay the release of generic versions of two pain relievers—Lidoderm and Opana ER—in order to preserve monopoly profits, the ...